Rationale and design of the DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes) A multicenter retrospective nationwide Italian study and crowdsourcing opportunity

被引:25
作者
Fadini, G. P. [1 ]
Zatti, G. [1 ]
Consoli, A. [2 ]
Bonora, E. [3 ]
Sesti, G. [4 ]
Avogaro, A. [1 ]
机构
[1] Univ Padua, Dept Med, I-35128 Padua, Italy
[2] Univ G dAnnunzio, Dept Med & Aging Sci, I-68100 Chieti, Italy
[3] Univ Verona, Dept Med, I-37154 Verona, Italy
[4] Magna Graecia Univ Catanzaro, Dept Med & Surg Sci, I-88100 Catanzaro, Italy
关键词
Randomized controlled trial; Retrospective study; Sodium glucose co-transporter-2 inhibitor; Real-life; GLUCOSE-LOWERING DRUGS; ALL-CAUSE MORTALITY; GLYCEMIC CONTROL; BLOOD-PRESSURE; BODY-WEIGHT; LOWER RISK; FAT MASS; THERAPY; METFORMIN; MELLITUS;
D O I
10.1016/j.numecd.2017.08.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Randomized controlled trials (RCTs) in the field of diabetes have limitations inherent to the fact that design, setting, and patient characteristics may be poorly transferrable to clinical practice. Thus, evidence from studies using routinely accumulated clinical data are increasingly valued. Aims: We herein describe rationale and design of the DARWIN-T2D (DApagliflozin RealWorld evIdeNce in Type 2 Diabetes), a multicenter retrospective nationwide study conducted at 50 specialist outpatient clinics in Italy and promoted by the Italian Diabetes Society. Data synthesis: The primary objective of the study is to describe the baseline clinical characteristics (particularly HbA1c) of patients initiated on dapagliflozin from marketing authorization approval to the end of 2016. Secondary and exploratory objectives will evaluate the changes in glycaemic and extraglycaemic efficacy parameters after initiation of dapagliflozin or after initiation of comparator glucose lowering medications (DPP-4 inhibitors, gliclazide extended release, and long-acting GLP-1 receptor agonists). An automated software will extract relevant data from the same electronic chart system at all centres, thereby minimizing data treatment and human intervention. Conclusion: The study is expected to collect an enormous dataset of information on dapagliflozin- and comparator-using patients. After study completion, the Italian Diabetes Society will launch an open crowdsourcing call on the DARWIN-T2D database, challenging diabetes researchers to apply their ideas and approaches to address new unmet needs and knowledge gaps in diabetes. We believe this will move DARWIN-T2D to the next generation of real world studies. (c) 2017 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:1089 / 1097
页数:9
相关论文
共 50 条
  • [1] Use and effectiveness of dapagliflozin in patients with type 2 diabetes mellitus: a multicenter retrospective study in Taiwan
    Chen, Jung-Fu
    Peng, Yun-Shing
    Chen, Chung-Sen
    Tseng, Chin-Hsiao
    Chen, Pei-Chi
    Lee, Ting-, I
    Lu, Yung-Chuan
    Yang, Yi-Sun
    Lin, Ching-Ling
    Hung, Yi-Jen
    Chen, Szu-Ta
    Lu, Chieh-Hsiang
    Yang, Chwen-Yi
    Chen, Ching-Chu
    Lee, Chun-Chuan
    Hsiao, Pi-Jung
    Jiang, Ju-Ying
    Tu, Shih-Te
    PEERJ, 2020, 8
  • [2] A Multinational Real-World Study on the Clinical Characteristics of Patients with Type 2 Diabetes Initiating Dapagliflozin in Southern Europe
    Fadini, Gian Paolo
    Tentolouris, Nikolaos
    Mateos, Irene Caballero
    Castaneda, Virginia Bellido
    Portillo, Cristobal Morales
    DIABETES THERAPY, 2020, 11 (02) : 423 - 436
  • [3] A Retrospective Real-World Study of Dapagliflozin Versus Other Oral Antidiabetic Drugs Added to Metformin in Patients with Type 2 Diabetes
    Huang, Huan
    Bell, Kelly F.
    Gani, Ray
    Tugwell, Cathy W.
    Eudicone, James M.
    Krukas-Hampel, Michelle R.
    AMERICAN JOURNAL OF MANAGED CARE, 2018, 24 (08) : S132 - S137
  • [4] The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real-world observational study
    McGurnaghan, Stuart J.
    Brierley, Liam
    Caparrotta, Thomas M.
    McKeigue, Paul M.
    Blackbourn, Luke A. K.
    Wild, Sarah H.
    Leese, Graham P.
    McCrimmon, Rory J.
    McKnight, John A.
    Pearson, Ewan R.
    Petrie, John R.
    Sattar, Naveed
    Colhoun, Helen M.
    DIABETOLOGIA, 2019, 62 (04) : 621 - 632
  • [5] Effects of dapagliflozin on renal function in type 1 diabetes patients in the real world: A retrospective multicenter study of the KAMOGAWA-A cohort
    Hironaka, Junya
    Okada, Hiroshi
    Hamaguchi, Masahide
    Sakai, Kimiko
    Minamida, Megumi
    Kondo, Yuriko
    Hashimoto, Yoshitaka
    Kitagawa, Noriyuki
    Yano, Miho
    Yamazaki, Masahiro
    Hasegawa, Goji
    Horiguchi, Go
    Teramukai, Satoshi
    Fukui, Michiaki
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2023, 202
  • [6] Use of Dapagliflozin in the Management of Type 2 Diabetes Mellitus: A Real-World Evidence Study in Indian Patients (FOREFRONT)
    Viswanathan, Vijay
    Singh, K. P.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2019, 21 (08) : 415 - 422
  • [7] Rationale and Design of the Vitamin D and Type 2 Diabetes (D2d) Study: A Diabetes Prevention Trial
    Pittas, Anastassios G.
    Dawson-Hughes, Bess
    Sheehan, Patricia R.
    Rosen, Clifford J.
    Ware, James H.
    Knowler, William C.
    Staten, Myrlene A.
    DIABETES CARE, 2014, 37 (12) : 3227 - 3234
  • [8] Efficacy of a Combination of Metformin and Vildagliptin in Comparison to Metformin Alone in Type 2 Diabetes Mellitus: A Multicentre, Retrospective, Real-World Evidence Study
    Mohan, Viswanathan
    Zargar, Abdul
    Chawla, Manoj
    Joshi, Ameya
    Ayyagari, Usha
    Sethi, Bipin
    Gaurav, Kumar
    Patted, Usha Rani H.
    Bhagat, Seema Vikas
    Mane, Amey Ishwara
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2021, 14 : 2925 - 2933
  • [9] Real-world safety and effectiveness of dapagliflozin in people living with type 1 diabetes in Spain: The Dapa-ON multicenter retrospective study
    Duran-Martinez, Maria a b
    Azriel, Sharona b c
    Doulatram-Gamgaram, Viyey Kishore d
    Moreno-Perez, Oscar e f
    Pines-Corrales, Pedro J. g
    Tejera-Perez, Cristina h
    Merino-Torres, Juan Francisco i j k
    Brito-Sanfiel, Miguel l
    Chico, Ana m n o
    Marco, Amparo b p
    Garcia-Fernandez, Elena q
    Martinez-Montoro, Jose Ignacio r s t u
    DIABETES & METABOLISM, 2024, 50 (01)
  • [10] Predicting diabetic kidney disease for type 2 diabetes mellitus by machine learning in the real world: a multicenter retrospective study
    Liu, Xiao Zhu
    Duan, Minjie
    Huang, Hao Dong
    Zhang, Yang
    Xiang, Tian Yu
    Niu, Wu Ceng
    Zhou, Bei
    Wang, Hao Lin
    Zhang, Ting Ting
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14